Table Of Content

Breast Cancer Research and Treatment 39: 353-354, 1996. Author index, Volume 39 Adhikarakunnathu S Das BC 197 Javier R 45 Nilsson B 213 293 DaskalI 221 Johannessen DC 335 Nogués C 275 Adlercreutz H 335 de la Rochefordiére A Adriaansen-Slot GEJ 275 Kalman E 221 Ofner D 165 139 de Vries EGE 307 Kelly V 155 Aldaz CM_ 177 Demicheli R 285 Kern FG 103 Pouillart P 275 Amundadottir LT 119 Dhingra K 177 Kharbanda S_ 103 Price JE 93 Andersen KW 321 Dickson RB_ 103,119 Kristensen B 321 Pronzato P 235 Dolsma WV 307 KurebayashiJ 103 Balsara BR 343 Dow KH 261 Kuroishi T 315 Rao RS 343 Berghorn M 165 Diinser M 165 Repetto L 235 Berland E 327 Lah TT 221 Rijksen G 139 Bhat AV 343 Ejlertsen B 321 Langer D 165 Rodenhuis S 307 Bhisey AN 343 Ekse D 335 Lauritzen JB 321 Rosso R 235 Bier B 165 Elliott RL 349 Le-Nir CC-S 275 Rostagno P 147 Birtwisle-Peyrottes I Estrada S 221 Lebesque JV 307 Rostaing-Puissant B 327 147 Ettore F 147 Leigh S 261 RussoI 7 Blijham GH 307 Lidereau R 275 Russo J 7,221 Blijham GH 239 Faaland CA 293 Lippman ME 103 Boécker W_ 165 Ferrari L 285 Loénn S 213 Sahin A 177 Bolla M 327 Ferrell BR 261 Loénn U 213 Salero E 221 Bonadonna G 285 Fluck MM 45 Lgnning PE 335 Samson W 203 Bontenbal M 307 Lowther GW 247 Schmid KW 165 Bottari SP 327 Giannessi PG 235 Ly J 261 Scholl SM 275 Brambilla C 285 Gilchrist KW 203 Schouten HC 307 Briinner N 87 Gopalkrishna V 197 Mandal AK 197 Sharma JK 197 Burrows FJ 241 Green JA 155 Manni A 187 Shenk T 45 Griffioen AW 239 Marron-Charriere J 327 Shimizu H 315 Calaf G 221 Grimes RW 187 Martini C 285 Shinde BG 221 Caldani C 147 Groenewegen G 239 Matsushita Y 315 Singh UR 197 Callahan R 33 Gulasekaram P 261 McCallum HM 247 Slater AJ 155 Campbell IR 155 McLeskey SW 103 Smith GH 21 Campora E 235 Hagemann H-A 165 Meisner LF 203 Sneige N 177 Caraceni A 285 Hammond JM 187 Merlino G 119 Sodhani P 197 Chambaz 327 Harris CP 203 Moliterni A 285 Somers R 221 Chedin M 327 Haslam SZ 45 Moll J-L_ 147 Spang-Thomsen M 87 Chen T 177 Head JF 349 Morrow M 351 SpinelliI . 235 Clarke R 1,69 Hedau ST 197 Mosseri V 275 Staal EJ 139 Colonna M 327 Heinrichs S 165 Mouridsen HT 321 Stanley ER 275 Conte PF 235 Helle SI 335 Mulder NH 307 Stenkvist B 213 Cullen K 87 Hortobagyi G 177 Hu Y-H 315 Nagata C 315 Terenziani M 285 Damen CA 239 Hupperets PSGJ 307 Naso C 235 Thomas T 293 354 Author index, Vol. 39 Thomas TJ 293 Thorpe PE 241 Varughese T 343 Vigani A 235 Xing W-R 203 Zambetti M 285 Zhang L_ 103 Breast Cancer Research and Treatment 39: 355-358, 1996. Subject index, Volume 39 adenovirus cell lines human adenovirus type 9 in rat mammary from primary breast tumor cultures, in defined fibroadenoma model 57-67 medium 247-259 AgNORs (silver-staining nucleolar organizer chemotherapy regions) doxorubicin vs. mitoxantrone, both with cytoxan as a prognostic factor 165-176 and vincristine 155-163 allelotype high-dose, in complete remission 307-313 from single paraffin sections by microsatellite vinorelbine as an active, non-cross-resistant drug length polymorphism analysis 177-185 in advanced disease 285-291 angiogenesis inhibitors chromosome in situ hybridization AGM 1470 slows FGF-4/lacZ-transfected MCF- in interphase cytogenetic analysis of specific 7 cells in nude mice 103-117 genes and chromosome copy number 177- animal models of breast cancer 185 overview 1-6 colony-stimulating factor CSF-1 special issue 1-136 in serum, as an indicator of early metastatic antiestrogen relapse 275-283 ER during cell cycle in tamoxifen-resistant cytogenetics MCF-7 xenograft 147-154 in a case of prepubertal breast cancer 343-347 antiestrogen cytokines see also tamoxifen serum CSF-1 as an indicator of early metastatic autologous bone marrow transplantation relapse 275-283 in high-dose chemotherapy during complete remission 307-313 DMBA rat mammary tumors as an animal model of breast cancer 7-20 beta galactosidase doxorubicin FGF-4/lacZ-transfected MCF-7 in nude mouse vs. mitoxantrone, both with cytoxan and metastasis model 103-117 vincristine 155-163 biopsy technique ductal progenitors stereotactic core needle biopsy vs. excisional distinct from lobular progenitors 21-31 biopsy — discussion 349-351 birth season endocrine therapy no association with breast cancer risk in Japan no improvement of tamoxifen treatment response 315-319 by interferon-beta 235-238 c-erbB-2 oncogene see also tamoxifen see HER-2/neu endocrinology carcinogenesis studies in xenografts in different immune- DMBA rat mammary tumor model 7-20 deficient mice 68-86 cathepsins endothelial cells D, B, and L in ras-transformed human breast endoglin/CD 105 as a treatment target 239-242 epithelial cells estrogen receptor cell cycle genes during cell cycle in MCF-7 147-154 in transgenic mouse models of breast in cell lines from breast tumor primary cultures tumorigenesis 119-135 247-259 356 Subject index, Vol. 39 estrogen therapy IGF binding protein 3 and loss of IGF-II mRNA in T61 xenograft clearance/proteolysis inhibited by IGF ligands model 87-92 187-196 estrogens IGF-II postmenopausal plasma levels and shorter mRNA loss with endocrine therapy in T61 disease-free interval 335-341 xenograft model 87-92 image analysis fibroadenomas of ER during cell cycle in MCF-7 cells and generated by human adenovirus type 9 in rat xenografts 147-154 mammary gland 57-67 immunobiology fibroblast growth factors of different immune-deficient mice as xenograft FGF-4/lacZ-transfected MCF-7 cells in nude recipients 69-86 mouse metastasis model 103-117 immunodeficient mice fine-needle aspirates in metastasis model 93-102 PCR detection of HER-2/neu amplification 213- xenograft models of breast cancer 97-92 220 see also nude mice fluorescent in situ hybridization (FISH) insulin-like growth factors detection of HER-2/neu amplification in early- -see IGFs onset breast cancer 203-212 int genes and tumor progression — MMTV mouse model gene amplification 33-44 FISH detection of HER-2/neu amplification in in transgenic mouse models of breast early-onset breast cancer 203-212 tumorigenesis 119-135 PCR detection of HER-2/neu amplification in interferon-beta fine-needle aspirates 213-220 no improvement of tamoxifen treatment response genetic evolution 235-238 allelotype analysis technique from single internalization microdissected paraffin sections 177-185 not required for proteolytic clearance of IGFBP- genetics 3 by MCF-7 cells 187-196 detection of genes involved in tumor progression invasion in MMTV model 33-44 cathepsins D, B, and L in c-Ha-ras-transformed human breast epithelial cells HER-2/neu oncogene FISH detection of amplification in early-onset lobular progenitors breast cancer 203-212 distinct from ductal progenitors 21-31 PCR detection of amplification in fine-needle lysosomal proteases aspirates 213-220 cathepsins D, B, and L in ras-transformed high-dose chemotherapy human breast epithelial cells during complete remission 307-313 hormone dependence mammary epithelial development estrogen dependence of adenovirus type 9 separate ductal and lobular progenitor cells 21- generated rat mammary tumors 57-67 31 hormone replacement therapy mammary fat pad postmenopausal plasma estrogens and shorter orthotopic injection of MDA-MB-435 cells in disease-free interval 335-341 metastasis model 93-102 human papillomavirus (HPV) MCF-7 human breast cancer cells complete absence of HPV types 16 and 18 DNA FGF-4/lacZ-transfected MCF-7 in nude mouse in breast cancer (PCR) 197-202 metastasis model 103-117 Subject index, Vol. 39 357 MCF-7 human breast cancer cells (cont.) oncogenesis inhibition of growth and polyamine biosynthesis by polyomavirus in mouse mammary gland 45- by S-adenosyl methionine decarboxylase 56 inhibitors 293-306 osteoporosis estrogen receptor during cell cycle 147-154 no reduction in femoral fractures by tamoxifen IGFBP-3 clearance inhibited by IGF ligands 321-326 187-196 MDA-MB-435 cells papillomavirus in metastasis model 93-102 complete absence of HPV types 16 and 18 DNA metastasis in breast cancer (PCR) 197-202 serum CSF-1 as an indicator of early metastatic PCR relapse 275-283 complete absence of HPV types 16 and 18 DNA metastasis model in breast cancer 197-202 MDA-MB.-435 cells injected in the nude mouse in detection of HER-2/neu amplification in fine- mammary fat pad 93-102 needle aspirates 213-220 FGF-4/lacZ-transfected MCF-7 cells in nude pentosan polysulfate mice 103-117 slows FGF-4/lacZ-transfected MCF-7 cells in microdissection metastasis model 103-117 in allelotype analysis from single paraffin phyllodes tumor sections 177-185 generated by human adenovirus type 9 in rat mitoxantrone mammary gland 57-67 vs. doxorubicin, both with cytoxan and polyamines vincristine 155-163 inhibition of MCF-7 growth and polyamine MMTV (mouse mammary tumor virus) infected biosynthesis by S-adenosyl methionine mice decarboxylase inhibitors 293-306 model for detecting genes in tumor progression polymerase chain reaction 33-44 see PCR morphogenesis polyomavirus separate ductal and lobular progenitor cells 21- mouse mammary tumor model 45-56 31 prepubertal breast cancer mouse cell transplantation model cytogenetic analysis of a case 343-347 showing separate ductal and lobular progenitor primary breast tumor cultures cells 21-31 in defined medium 247-259 mouse models of breast cancer prognostic factors human xenografts in nude, scid, bg/nu, and other cytosolic tyrosine kinase activity 327-334 mouse recipients 69-86 FISH detection of HER-2/neu amplification 203-212 nucleolar organizer regions (AgNORs) increased AgNORs (silver-staining nucleolar as a prognostic factor 165-176 organizer regions) and early relapse 165-176 nude mice PCR detection of HER-2/neu amplification in and mouse polyomavirus mammary tumor fine-needle aspirates 213-220 model 45-56 serum CSF-1 as an indicator of early metastatic FGF-4/lacZ-transfected MCF-7 cells in relapse 275-283 metastasis model 103-117 protein tyrosine kinase oncogenes see tyrosine kinase E4 ORF1 adenovirus protein 57-67 psychological issues in transgenic mouse models of breast quality of life study among long-term breast tumorigenesis 119-135 cancer survivors 261-273 358 Subject index, Vol. 39 quality of life tumor evolution study of long-term breast cancer survivors 261- in the DMBA rat mammary tumor model 7-20 273 MMTV- infected mice as a model for detecting relevant genes 33-44 ras oncogenes tumorigenesis in transgenic mouse models of breast transgenic mouse models 119-135 tumorigenesis 119-135 tyrosine kinase cathepsins D, B, and L in c-Ha-ras-transformed as a possible prognostic factor 327-334 human breast epithelial cells ELISA assay for src-family kinase 139-145 risk factors no association of birth season with breast cancer vinorelbine risk in Japan 315-319 as an active, non-cross-resistant drug in advanced disease 285-291 S-adenosylmethionine decarboxylase inhibitors viral oncogenes inhibition of growth and polyamine biosynthesis middle T antigen in mouse polyomavirus in MCF-7 cells 293-306 mammary tumor model 45-56 serum markers CSF-1 as an indicator of early metastatic relapse xenografts 275-283 as breast cancer models in different recipient serum-free medium mice 69-86 breast tumor primary cultures 247-259 T61 human tumor model of estrogen therapy special issue 87-92 animal models of breast cancer 1-136 spermine inhibition of MCF-7 growth and polyamine biosynthesis by S-adenosyl methionine decarboxylase inhibitors 293-306 src tyrosine kinase ELISA assay with cdc2 peptide substrate 139- 145 stereotactic core needle biopsy vs. excisional biopsy — discussion 349-351 tamoxifen ER during cell cycle in resistant MCF-7 xenograft 147-154 no improvement of treatment response by interferon-beta no reduction in femoral fractures 321-326 terminal end buds as a target for carcinogenesis in rat model 7-20 tissue culture long-term culture of primary breast cancer in defined medium 247-259 transgenic mice bearing the mouse polyomavirus middle T antigen 45-56 in breast cancer models, review 119-135